Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices
Background: In Europe, off-patent biologicals and biosimilars are largely procured by means of tender procedures. The organization and design of tenders may play a key role in the evolving biosimilar market, and currently, it is not fully elucidated how tenders for off-patent biologicals and biosimi...
Saved in:
Main Authors: | Liese Barbier (Author), Steven Simoens (Author), Caroline Soontjens (Author), Barbara Claus (Author), Arnold G. Vulto (Author), Isabelle Huys (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
by: Yannick Vandenplas, et al.
Published: (2021) -
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022) -
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
by: Evelien Moorkens, et al.
Published: (2020) -
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
by: Yannick Vandenplas, et al.
Published: (2022)